Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisKeratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin conditionVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Vascular pathology in multiple sclerosis: mind boosting or myth busting?Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.IL-17 and VEGF are necessary for efficient corneal nerve regeneration.Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis.Specific roles for dendritic cell subsets during initiation and progression of psoriasis.Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone.An important role of lymphatic vessel activation in limiting acute inflammationAn important role of the SDF-1/CXCR4 axis in chronic skin inflammationUpregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma.The cutaneous vascular system in chronic skin inflammationEpigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsSignaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasisInhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet functionThree-dimensional model of mouse epidermis for experimental studies of psoriasis.VEGF-Trap decreases CD4+ T cells, Th17 cytokines improving psoriasis-like skin inflammation in KC-Tie2 miceAnti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.VEGF involvement in psoriasis.Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.Low-molecular-weight hyaluronan (LMW-HA) accelerates lymph node metastasis of melanoma cells by inducing disruption of lymphatic intercellular adhesion.Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes.Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages.Expression of IL-23, VEGF and TLR2/TLR4 on mononuclear cells after exposure to Pseudomonas aeruginosa.The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.AP1 transcription factors in epidermal differentiation and skin cancerVEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.Capillaroscopy in psoriatic and rheumatoid arthritis: a useful tool for differential diagnosisCan signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis?IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease.Targeting miR-21 to Treat Psoriasis
P2860
Q22305863-22D0E8AE-5170-47E2-9FFF-923DD2D0BC0AQ26822766-D038DCF4-4C43-4D29-8924-53CC89A316E5Q30469815-1CFD3DE1-2364-4DA6-9F71-62EC3CCDD212Q30471456-F897E51E-9294-4663-87AF-4D64B7867CFBQ33960741-122087C7-4F8C-44DA-B1E0-DE3533441276Q34161479-6D5A07AD-3324-4D6B-9E8D-11A63B264740Q34755584-03515F31-E951-47E9-959D-4D6825D58596Q34800330-1B268C77-EFFE-4644-B825-5023C1D5A2E7Q34880408-D08D5119-F8EC-4A46-A062-DD49BEFF32E4Q34997498-E0EF7B03-D89F-4BA8-865C-048C61702933Q34997755-6E9DB7EF-728B-455D-ACB7-EFD4930EA625Q35138679-95BEB2A5-EF48-4A7D-9633-8748FDC4FAC8Q35173651-0D53386D-BB72-4662-8D28-9F24BE07440DQ36098582-F365F2AB-BA1D-4352-97D4-5FC956085D90Q36118883-91F77255-D204-4AA4-9DE3-589B1E8D6BA2Q36158922-6B0B71F4-8663-4D63-B87E-7392005E6891Q36754425-FB8C081A-C041-4991-B6E4-529C318F8904Q37031073-1494C632-D197-4DDA-B80A-FA9E617E7339Q37475600-8E448E22-ADAF-4EDC-9A23-0E397210F6F5Q37588025-7BA42067-5FFD-47AF-B23F-6B530EB6D39BQ38365380-D5BA37C4-0ECD-47E0-995A-A25B69EEDF8CQ38648336-42FD9D54-13CF-4190-811C-807224B564A6Q38728552-62614F52-D947-4E0A-8C01-AF3DBF894FACQ39079697-DB3AD193-C2A6-4C5A-8E62-CDE18670BC7CQ39207790-5BA1A50B-C3D8-42A8-9C24-F6EC5DF70C91Q39409408-83209CA1-7C90-406A-9BB2-3CFDE47B8F83Q39414999-EE70A442-7230-4AF1-8063-ADD5733B0C73Q41354182-6BBA976E-A816-4D5D-B692-D300F75606D3Q41878046-641D89A4-0362-47CF-84B1-A319B6A23C9EQ42080847-12D3FB5B-EF6F-49BC-AC5C-FD4EFC496CD7Q42772956-DEE7E44F-511F-404F-A05B-737EBC0DA515Q51122128-1C284F12-3221-4ED9-9ED1-26613E102B32Q52802857-38E8E4DD-E889-4CD1-8AFC-506B24F5418AQ54956609-8502BF67-8AFF-498F-9950-FCF2DC947DFCQ57826324-ADAB2C9E-0296-49A5-9C0B-667C6CD70C48
P2860
Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@en
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@nl
type
label
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@en
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@nl
prefLabel
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@en
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@nl
P2860
P50
P356
P1476
Systemic anti-VEGF treatment s ...... in a mouse model of psoriasis.
@en
P2093
Helia B Schonthaler
Reto Huggenberger
P2860
P304
21264-21269
P356
10.1073/PNAS.0907550106
P407
P577
2009-12-07T00:00:00Z